Le Lézard
Classified in: Health, Science and technology
Subjects: Survey, Funding

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria


Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The Company will use the funding to establish laboratories in Oxford and Glasgow and expand its team to accelerate its bacteriocin development programme. The investment round was led by Boehringer Ingelheim Venture Fund and Scottish Enterprise.

Antimicrobial resistance (AMR) is a major public health crisis throughout the world. It is estimated that around 1.27 million people per year die as a result of AMR due to the therapeutic failure of available antibiotics.* By 2050, AMR is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion dollars; hence, there is an urgent need to develop new effective antimicrobial therapeutics.**

Glox Therapeutics is developing precision antibiotics utilising engineered protein bacteriocins. These novel antimicrobials exhibit remarkable potency and specificity, enabling them to effectively and selectively target Gram-negative pathogens that have already developed AMR, including Pseudomonas aeruginosa and Klebsiella pneumoniae. Bacteriocins, which are naturally produced by bacteria, possess antimicrobial properties against strains of the same or related species. Leveraging the power of bacteriocins, Glox Therapeutics aims to advance the field of antimicrobial therapy by overcoming resistance to traditional antibiotics. It will focus on selectively eradicating target pathogens while preserving the patient's microbiomes, ensuring a more balanced and effective treatment strategy with reduced side-effects.

The Company was founded in February 2023 by recognised leaders in the bacteriocin field: Prof Daniel Walker from the University of Glasgow (now at the University of Strathclyde) and Prof Colin Kleanthous, Fellow of the Academy of Medical Sciences (FMedSci), from the University of Oxford. Dr James Clark was appointed as CEO in April this year. He has been involved in precision medicine for 25 years and has extensive C-suite level experience in the development and commercialisation of diagnostic and therapeutic products at PredictImmune, EnteroBiotix, Inivata, Enterome, MDxHealth and GSK.

"Our mission is to provide physicians and patients with highly potent, targeted antimicrobial therapies that can kill antibiotic-resistant bacteria for which there are diminishing options available for treatment," said Dr James Clark, CEO, Glox Therapeutics. "This seed funding is testament to the promise of Glox Therapeutics' precise antibiotic therapies, and we are thrilled to have the backing of such high-calibre investors. This will enable us to establish laboratories and attract top-tier talent, and I'm delighted to lead the team as we embark on our pioneering bacteriocin development programme, with the first target being P. aeruginosa," he added.

Uzma Khan, Vice Principal Economic Development and Innovation, University of Glasgow, said: "Bacteriocins offer the precision needed to target pathogens resistant to current treatments. Our novel platform, developed in collaboration with the University of Oxford, circumvents problems traditionally associated with using bacteriocins as therapeutics. We look forward to seeing the Company carry this forward to help deliver Gram-negative antimicrobial drugs."

Prof Chas Bountra, Pro Vice-Chancellor for Innovation, University of Oxford, said: "There is a growing consensus that the next generation of antibiotics should be narrow-spectrum therapeutics, able to target specific pathogenic AMR bacteria without collateral damage to the wider human microbiome, which is so vital to our health and wellbeing. Glox Therapeutics' high-potency therapies offer the long-awaited solution to address these urgent unmet medical needs in tackling treatment-resistant bacterial infections."

Dr Niklas Czeloth, Executive Director / Investment Manager, Boehringer Ingelheim Venture Fund, said: "The Boehringer Ingelheim Venture Fund is excited to invest in Glox Therapeutics, thereby advancing the development of its ground-breaking class of bacteriocins. In a world grappling with the escalating threat of AMR, there is an urgent global need for innovative approaches that target novel mechanisms devoid of any pre-existing resistance. We firmly believe that Glox Therapeutics holds immense potential to make a profound impact in the battle against antibiotic-resistant infections."

Kerry Sharp, Director of Entrepreneurship and Investment, Scottish Enterprise, said: "Glox Therapeutics is a fantastic example of an ambitious spin-out that's commercialising world-class life sciences research with the potential to save lives worldwide. The calibre of Scottish early-stage companies, like Glox Therapeutics, continues to attract international investment, enabling our youngest companies to positively contribute to Scotland's economy as they scale up."

For more information about Glox Therapeutics, please visit: https://gloxtherapeutics.com/

* Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
** Tackling Drug-Resistant Infections Globally: final report and recommendations


These press releases may also interest you

at 21:30
The "Hydroxypropyl Methylcellulose Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to  ResearchAndMarkets.com's offering. The latest industry analysis on the Hydroxypropyl Methylcellulose...

at 21:00
The "Asia-Pacific Contrast Media Agent and Injector System Market - Analysis and Forecast, 2022-2026" report has been added to  ResearchAndMarkets.com's offering. The Asia-Pacific contrast media agent and injector system market was valued at $1.98...

at 20:50
Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its  underwritten public offering of 6,471,000...

at 20:34
The Honourable Mark Holland, Minister of Health, will make an announcement related to An Act Respecting Pharmacare. There will be a virtual media technical briefing with Government of Canada officials prior to the press conference. DateFebruary 29,...

at 19:30
The "Protein Expression Market - A Global and Regional Analysis: Focus on Application, End User, Product, Expression System, and Region - Analysis and Forecast, 2023-2033" report has been added to  ResearchAndMarkets.com's offering. The global...

at 19:20
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, today announced that MSCI, one of the...



News published on and distributed by: